FTC Actions On Supplement Claim Substantiation Put Industry On Alert
This article was originally published in The Tan Sheet
Executive Summary
Substantiation “is not defined by one study or two studies and by whether the FTC likes that study or not,” attorney Todd Harrison says at CRN’s annual convention. Scott Bass, an attorney who worked on writing DSHEA, says “FTC has declared, at least informally, ‘We don’t care about FDA law.’”
You may also be interested in...
‘Wrong Type Of Expert’ Advised FTC On Phillip’s Colon Health Claims – CRN
FTC’s request that Bayer support claims for Phillip’s Colon Health probiotic supplement with RCTs would set a precedent that would invalidate most structure/function claims, CRN argues, saying FTC’s interpretation of competent and reliable evidence for structure/function claims disregards a wealth of scientific data.
Fair Standard Remains For Supplement, Drug Claim Substantiation – FTC
The Federal Trade Commission says consent orders that require more clinical tests to substantiate health claims than are required for other product categories are fair because they are based on the nature of the claims, agency officials say.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.